Poster: CML-231 Long-Term Results of Tyrosine Kinase Inhibitors Discontinuation in Patients With Chronic Myeloid Leukemia

The probability of MMR loss after 5 years of follow-up was 53%. Molecular relapses were rare after 2 years without TKI therapy. However, molecular monitoring with a frequency of 2-3 times a year during long-term observation in TFR is mandatory for patients' safety, especially in those with detectable MRD.